 In summary, this research has demonstrated the feasibility of using E.col and Coal Peptids as a tool for affinity-based delivery systems. The E.col Peptid Tag Trustuzumab was successfully produced in CHO cells and showed no effect on antibody binding to its antigen. Additionally, the E.col Tag Trustuzumab was released from macroporous dextran hydrogels in a biphasic manner, with the first phase corresponding to the rapid release of residual, unbound trustuzumab from the macropores, followed by the slower rate of release of antibodies from the Coal functionalised macropore surface. This suggests that the E.col Coal system can be used to develop a novel platform for controlled and sustained delivery of therapeutics. This article was authored by Seid Fazad Binay Ahmad, Romain Oliverio, Inns Oprecon Gomez, and others.